Level C· Early human research exploring benefitsProspective StudyPubMed

Effects of adipocyte-derived stem cells treatment for moderate radiodermatitis: animal model.

Camargo CP., Zavala JPM., Serafim GP., Carvalho HA., Santos BL., Nunes VA.

Prospective Study with a reported sample of 10 on Chronic Wound, published in Int J Radiat Biol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Int J Radiat Biol (2025)
Country
England
Reported sample size
10
Source database
PubMed
PMID
40455865
DOI
10.1080/09553002.2025.2505534
Citations
1

Abstract (original English)

Purpose Cancer treatment frequently involves the use of radiotherapy, which is associated with several adverse effects, including fatigue, immunosuppression, and radiodermatitis. Radiodermatitis affects up to 95% of patients worldwide. This study aimed to evaluate the therapeutic potential of adipose-derived stem cells (ASCs) in treating radiodermatitis in a rat model. Materials and methods Inguinal fat of three rats was removed, and ASC isolated. Then, 20 male Wistar rats underwent radiodermatitis induction using two Strontium-90 plaques, each delivering a single dose of 18 Gy to dorsal areas. After 15 days, animals were divided into two groups. (1) Control group ( n = 10): without treatment; (2) ASC group ( n = 10): treated with subcutaneous 1 × 10 6 ASC injections into radiodermatitis sites. After 15 more days, skin was evaluated with RTOG scale, and tissue samples were collected to perform histology and gene expression of inflammatory markers. Results ASC group showed a lower degree of radiodermatitis according to the RTOG scale. ASC showed an increased number of arterioles ( p = .007) and a reduction in number of inflammatory cells ( p = .02) compared to control. Furthermore, the treatment led to approximately a 50% reduction in the gene expression levels of the inflammation markers Il1rap ( p Mmp3 ( p = .001), and Tnf ( p = .004) as well as a 30% reduction in Cd68 ( p = .

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
AnimalsRadiodermatitisMaleRats, WistarRatsAdipocytesDisease Models, AnimalStem Cell TransplantationStem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research